Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4.1% | 14.5% | 12.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.8% | 81.7% | 79.4% | 77.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2% | -3.9% | -13.6% | -24.4% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2.2% | -4.6% | -13.2% | -23.9% |
| EPS | 0.057 | -0.12 | -0.3 | -0.49 |
| % Growth | 147.8% | 60% | 38.8% | – |
| EPS Diluted | 0.05 | -0.12 | -0.3 | -0.49 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 6.8% | 3.3% | -3.6% | -14.8% |